← Back to Clinical Trials
Recruiting NCT05733091

NCT05733091 Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05733091
Status Recruiting
Phase
Sponsor M.D. Anderson Cancer Center
Condition Tumors
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2018-12-20
Primary Completion 2029-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Standard of Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2018-12-20 with a primary completion date of 2029-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To learn about the symptoms and changes our patients experience while receiving treatment for sinonasal or nasopharyngeal cancer

Eligibility Criteria

Inclusion criteria: 1. Previously untreated patients with or suspected to have sinonasal malignancy or nasopharyngeal malignancy diagnosis based on either outside pathology report or MD Anderson pathology report. 2. Age ≥ 18 years 3. Plan to obtain the majority of treatment at MDACC including surgery and radiotherapy 4. Ability to understand and willingness to sign written informed consent Exclusion criteria: 1. History of the previous solid or liquid malignancies, apart from skin cancers treated with local therapy. 2. Existing neurocognitive impairment that is not the result of sinonasal and nasopharyngeal cancers or is treatment. 3. Previous treatment for sinonasal or nasopharyngeal carcinomas, apart from biopsy.

Contact & Investigator

Central Contact

Shirley Su, MBBS

✉ sysu@mdanderson.org

📞 (713) 792-4720

Principal Investigator

Shirley Su, MBBS

PRINCIPAL INVESTIGATOR

M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT05733091 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05733091 currently recruiting?

Yes, NCT05733091 is actively recruiting participants. Contact the research team at sysu@mdanderson.org for enrollment information.

Where is the NCT05733091 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT05733091 clinical trial?

NCT05733091 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Shirley Su, MBBS at M.D. Anderson Cancer Center. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology